Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-000623-13
    Sponsor's Protocol Code Number:VIR-7831-5008
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:
    Date on which this record was first entered in the EudraCT database:2021-10-12
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2021-000623-13
    A.3Full title of the trial
    A Phase 3 randomized, multi-center, open label study to assess the efficacy, safety, and tolerability of monoclonal antibody VIR-7831 (sotrovimab) given intramuscularly versus intravenously for the treatment of mild/moderate coronavirus disease 2019 (COVID-19) in high-risk non hospitalized patients
    Studio di fase 3 randomizzato, multicentrico, in aperto volto a valutare l'efficacia, la sicurezza e la tollerabilità della somministrazione per via intramuscolare dell'anticorpo monoclonale VIR-7831 (sotrovimab) rispetto alla somministrazione per via endovenosa nel trattamento della malattia da coronavirus 2019 (COVID-19) lieve/moderata in pazienti non ospedalizzati ad alto rischio
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Phase 3 study to assess the efficacy, safety, and tolerability of monoclonal antibody VIR-7831 (sotrovimab) given intramuscularly versus intravenously for the treatment of mild/moderate coronavirus disease 2019 (COVID-19) in high-risk non hospitalized patients
    Studio di fase 3 per valutare l'efficacia, la sicurezza e la tollerabilità della somministrazione per via intramuscolare dell'anticorpo monoclonale VIR-7831 (sotrovimab) rispetto alla somministrazione per via endovenosa nel trattamento della malattia da coronavirus 2019 (COVID-19) lieve/moderata in pazienti non ospedalizzati ad alto rischio
    A.3.2Name or abbreviated title of the trial where available
    Intramuscular VIR-7831 (sotrovimab) for mild/moderate COVID-19 Study Phase: Phase III
    VIR-7831 (sotrovimab) per via intramuscolare per COVID-19 lieve/moderata Fase dello studio: Fase II
    A.4.1Sponsor's protocol code numberVIR-7831-5008
    A.7Trial is part of a Paediatric Investigation Plan Yes
    A.8EMA Decision number of Paediatric Investigation PlanP/024/2021
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorVir Biotechnology, Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportVir Biotechnology, Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationPharmaceutical Product Development -PPD
    B.5.2Functional name of contact pointCarla Cafè
    B.5.3 Address:
    B.5.3.1Street AddressSegreen Business Park, Palazzo Y, via san Bovio 3
    B.5.3.2Town/ citySegrate
    B.5.3.3Post code20054
    B.5.3.4CountryItaly
    B.5.4Telephone number+3902210811
    B.5.5Fax number+390221081228
    B.5.6E-mailspasiaitalyregulatory@ppd.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namesotrovimab
    D.3.2Product code [VIR-7831]
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNSotrovimab
    D.3.9.1CAS number 2423014-07-5
    D.3.9.2Current sponsor codeVIR-7831 (GSK4182136) or WBP2275
    D.3.9.4EV Substance CodeSUB214951
    D.3.10 Strength
    D.3.10.1Concentration unit µg/ml microgram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number62500
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeVIR-7831 è un anticorpo monoclonale (mAb) IgG1 kappa (IgG1¿) completamente umano derivato dal mAb parentale S309, un potente mAb diretto contro la proteina spike del SARS-CoV-2
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namesotrovimab
    D.3.2Product code [VIR-7831]
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntramuscular use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNSotrovimab
    D.3.9.1CAS number 2423014-07-5
    D.3.9.2Current sponsor codeVIR-7831 (GSK4182136) or WBP2275
    D.3.9.4EV Substance CodeSUB214951
    D.3.10 Strength
    D.3.10.1Concentration unit µg/ml microgram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number62500
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeVIR-7831 è un anticorpo monoclonale (mAb) IgG1 kappa (IgG1¿) completamente umano derivato dal mAb parentale S309, un potente mAb diretto contro la proteina spike del SARS-CoV-2
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namesotrovimab
    D.3.2Product code [VIR-7831]
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntramuscular use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNSotrovimab
    D.3.9.1CAS number 2423014-07-5
    D.3.9.2Current sponsor codeVIR-7831 (GSK4182136) or WBP2275
    D.3.9.4EV Substance CodeSUB214951
    D.3.10 Strength
    D.3.10.1Concentration unit µg/ml microgram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number62500
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeVIR-7831 è un anticorpo monoclonale (mAb) IgG1 kappa (IgG1¿) completamente umano derivato dal mAb parentale S309, un potente mAb diretto contro la proteina spike del SARS-CoV-2
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Mild/moderate COVID-19
    COVID-19 lieve/moderata
    E.1.1.1Medical condition in easily understood language
    Mild/moderate coronavirus disease 2019 (COVID-19)
    malattia da coronavirus 2019 (COVID-19) lieve/moderata
    E.1.1.2Therapeutic area Diseases [C] - Virus Diseases [C02]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 23.1
    E.1.2Level LLT
    E.1.2Classification code 10084401
    E.1.2Term COVID-19 respiratory infection
    E.1.2System Organ Class 10021881 - Infections and infestations
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 23.0
    E.1.2Level PT
    E.1.2Classification code 10084268
    E.1.2Term COVID-19
    E.1.2System Organ Class 10021881 - Infections and infestations
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Evaluate the efficacy of two dose levels of intramuscular (IM) VIR-7831 versus (vs) intravenous (IV) VIR-7831 in preventing the progression of mild/moderate COVID-19
    Valutare l'efficacia di due livelli di dosaggio di VIR-7831 per via intramuscolare (IM) rispetto a VIR-7831 per via endovenosa (EV) nel prevenire la progressione della COVID-19 lieve/moderata
    E.2.2Secondary objectives of the trial
    1-Describe safety and tolerability of IM and IV VIR-7831
    2-Assess VIR-7831 immunogenicity
    3-Evaluate two dose levels efficacy of IM vs IV VIR-7831 on mild/moderate COVID-19 progression
    4-Evaluate two dose levels efficacy of IM vs IV VIR-7831 in preventing COVID-19 respiratory disease progression
    5-Compare VIR-7831 virologic activity given IM (two dose leves) or IV in reducing SARS-CoV-2 viral load
    6-Assess VIR-7831 pharmacokinetics in serum following IV and IM administration
    7-Describe effect of two dose levels of IM vs IV VIR-7831 on incidence and duration of time on total hospital length of stay, incidence and duration of time on a ventilator, and ICU length of stay
    8-Monitor SARS-CoV-2 resistant mutants against VIR-7831
    9-Compare VIR-7831 virologic activity given IM (two dose leves) or IV in reducing SARS-CoV-2 viral load
    10-Compare effect of different sample collection methods in SARS-CoV-2 viral load
    11-Evaluate VIR-7831 effect on the development of SARS-CoV-2 antibodies
    1-Descrivere sicurezza e tollerabilità di VIR-7831 IM e EV
    2-Valutare l'immunogenicità
    3-l'efficacia di 2 livelli di dosi IM rispetto a EV sulla progressione di COVID-19 lieve/moderata
    4-l’efficacia di 2 livelli di dosi IM rispetto a EV nella prevenzione della progressione della malattia respiratoria da COVID-19
    5-Confrontare l'attività virologica IM (due livelli di dosaggio) o EV nel ridurre la carica virale di SARS-CoV-2
    6-Valutare la farmacocinetica nel siero dopo la somministrazione EV e IM
    7-Descrivere l'effetto di 2 livelli di dosi IM rispetto a EV sull'incidenza e la durata della degenza ospedaliera totale, della ventilazione e in terapia intensiva
    8-Monitorare i mutanti di SARS-CoV-2 con resistenza a VIR-7831
    9-Confrontare l'attività virologica IM (2 livelli di dosaggio) o EV nel ridurre la carica virale di SARS-CoV-2
    10-Confrontare l'effetto dei diversi metodi di raccolta dei campioni sulla carica virale
    11-Valutare l'effetto sullo sviluppo degli anticorpi contro SARS-CoV-2
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives

    Other types of substudies
    Specify title, date and version of each substudy with relative objectives: Saliva SARS-CoV-2 qRT-PCR sub-study
    To evaluate the comparability of SARS-CoV-2 quantitative RT-PCR when performed on saliva versus nasopharyngeal (NP) swabs, an optional sub-study will be performed. Up to 200 subjects will have paired saliva and NP collected at 4 timepoints during the study (D1, D8, D15, D22).

    Altre tipologie di sottostudi
    specificare il titolo, la data e la versione di ogni sottostudio con i relativi obiettivi: Sottostudio qRT-PCR per SARS-CoV-2 nella saliva.
    Per valutare la comparabilità del test RT-PCR quantitativo per SARS-CoV-2 quando viene eseguito sulla saliva rispetto ai tamponi nasofaringei (NP), sarà eseguito un sottostudio facoltativo. Fino a 200 soggetti saranno sottoposti a raccolta di campioni di saliva e NP abbinati in 4 momenti definiti durante lo studio (G1, G8, G15, G22).
    E.3Principal inclusion criteria
    AGE AND RISK FACTORS
    1. Participant must be aged 12 years or older at time of consent AND at
    high risk of progression of COVID-19 based on the presence of one or
    more of the following risk factors:
    a. For 12-17 years old: diabetes, obesity (BMI =85th percentile for
    age/gender based on CDC growth charts), chronic kidney disease (e.g.
    eGFR <60), sicklecell disease, congenital heart disease,
    neurodevelopmental disorders, chronic lung diseases (i.e. chronic
    obstructive pulmonary disease, moderate to severe asthma requiring
    steroids, interstitial lung disease, cystic fibrosis, and pulmonary
    hypertension), immunosuppressive disease or immunosuppressive
    medications, or chronic liver disease
    b. For 18-54 years old: diabetes (requiring medication), obesity (BMI =
    30, chronic kidney disease (i.e., eGFR <60 by MDRD), congenital heart
    disease, congestive heart failure (NYHA class II or more), chronic lung
    diseases (i.e. chronic obstructive pulmonary disease, moderate to severe
    asthma requiring steroids, interstitial lung disease, cystic fibrosis, and
    pulmonary hypertension), sickle cell disease, neurodevelopmental
    disorders, immunosuppressive disease or receiving immunosuppressive
    medications, or chronic liver disease
    OR
    2. Participant = 55 years old, irrespective of co-morbidities
    TYPE OF PARTICIPANT AND DISEASE CHARACTERISTICS
    3. Participants who have a positive SARS-CoV-2 test result within 7 days
    of randomization (by any validated diagnostic test e.g. RT-PCR, antigen
    based testing on any specimen type)
    AND
    4. Oxygen saturation =94% on room air
    AND
    5. Have symptoms of COVID-19 defined by one or more of the following:
    fever, chills, cough, sore throat, malaise, headache, joint or muscle pain,
    change in smell or taste, vomiting, diarrhea, shortness of breath on
    exertion
    AND
    6. Participant to be dosed less than or equal to 7 days from onset of
    symptoms to dosing day (D1)
    SEX AND CONTRACEPTIVE/BARRIER REQUIREMENTS
    7. No gender restrictions
    8. Female participants must meet and agree to abide by the following
    contraceptive criteria. Contraception use by women should be consistent
    with local regulations regarding the methods of contraception for those
    participating in clinical studies.
    A female participant is eligible to participate if she is not pregnant or
    breastfeeding, and one of the following conditions applies:
    a. Is a woman of non-childbearing potential (WONCBP).
    OR
    b. Is a WOCBP and using a contraceptive method that is highly
    effective, with a failure rate of <1%, during the study intervention
    period and for up to 24 weeks after the last dose of study intervention.
    The investigator should evaluate potential for contraceptive method
    failure (e.g., noncompliance, recently initiated) in relationship to the
    first dose of study intervention.
    A WOCBP must have a negative highly sensitive pregnancy test (urine or
    serum as required by local regulations) before the first dose of study
    intervention.
    -If a urine test cannot be confirmed as negative (e.g., an ambiguous
    result), a serum pregnancy test is required. In such cases, the
    participant must be excluded from participation if the serum pregnancy
    result is positive.
    INFORMED CONSENT
    9. Capable of giving signed informed consent.
    OR
    10. If participants are not capable of giving written informed consent,
    alternative consent procedures will be followed as defined in Section
    10.1.3 of protocol.
    OR
    11. Participants <18 years old will be required to sign an assent form in
    addition to a parent or guardian signing the informed consent.
    ETÀ E FATTORI DI RISCHIO
    1. Il partecipante deve avere un'età >= 12 anni al momento del consenso ED essere ad alto rischio di progressione di COVID-19 in base alla presenza di 1 o più dei seguenti fattori di rischio:
    a. Per 12-17 anni: diabete, obesità (BMI =85°perc per età/sesso secondo le tabelle di crescita CDC), malattia renale cronica (es. eGFR <60), anemia falciforme, malattia cardiaca congenita, disturbi dello sviluppo neurologico, malattie polmonari croniche (ovvero, malattia polmonare ostruttiva cronica, asma moderata/grave che richiede l'uso di steroidi, malattia polmonare interstiziale, fibrosi cistica e ipertensione polmonare), malattia immunosoppressiva o farmaci immunosoppressivi o malattia epatica cronica
    b. Per 18-54 anni: diabete (che richiede terapia farmacologica), obesità (BMI =30), malattia renale cronica (ovvero, eGFR <60 secondo MDRD), malattia cardiaca congenita, insufficienza cardiaca congestizia (classe II o > secondo NYHA), malattie polmonari croniche (ovvero malattia polmonare ostruttiva cronica, asma da moderata a grave che richiede l'uso di steroidi, malattia polmonare interstiziale, fibrosi cistica e ipertensione polmonare), anemia falciforme, disturbi dello sviluppo neurologico, malattia immunosoppressiva o terapia con farmaci immunosoppressivi o malattia epatica cronica
    OPPURE
    2. Partecipante = 55 anni, indipendentemente dalle comorbilità
    TIPO DI PARTECIPANTE E CARATTERISTICHE DELLA MALATTIA
    3. Risultato positivo al test SARS-CoV-2 nei 7 giorni precedenti la randomizzazione (mediante qualsiasi test diagnostico convalidato, es. RT-PCR, test basato sull'antigene su qualsiasi tipo di campione)
    E
    4. Saturazione dell'ossigeno =94% ambiente
    E
    5. Sintomi di COVID-19 definiti come uno o più tra i seguenti: febbre, brividi, tosse, mal di gola, malessere, mal di testa, dolori articolari o muscolari, alterazioni di olfatto o gusto, vomito, diarrea, respiro corto sotto sforzo
    E
    6. Dall'inizio dei sintomi al giorno della somministrazione (G1) al partecipante deve intercorrere un periodo inferiore o uguale a 7 giorni
    ATTIVITÀ SESSUALE E REQUISITI DI CONTRACCEZIONE/DI BARRIERA
    7. Nessuna limitazione di genere
    8. Le partecipanti di sesso femminile devono soddisfare e accettare di rispettare i seguenti criteri contraccettivi. L'uso di contraccettivi da parte delle donne dovrà essere coerente con le normative locali relative ai metodi contraccettivi per coloro che partecipano a studi clinici.
    Una partecipante di sesso femminile è eleggibile a partecipare se non è incinta o in allattamento e se si applica almeno una delle seguenti condizioni:
    a. è una donna non potenzialmente fertile (WONCBP)
    OPPURE
    b. È una WOCBP e utilizza un metodo contraccettivo altamente efficace con una percentuale di insuccesso <1% durante il periodo di intervento in studio e per un periodo fino a 24 settimane dopo l’ultima dose di intervento in studio. Lo sperimentatore deve valutare il potenziale di insuccesso del metodo contraccettivo (per es. non conformità, iniziato di recente) in relazione alla prima dose di intervento in studio.
    Una WOCBP deve presentare un test di gravidanza a elevata sensibilità (su urine o siero secondo quanto richiesto dalle normative locali) negativo prima della prima dose di intervento in studio.
    - Se non può essere confermato un test sulle urine negativo (per es. risultato ambiguo), è necessario un test di gravidanza sul siero. In questi casi, la partecipante deve essere esclusa dalla partecipazione se il risultato del test di gravidanza sul siero è positivo.
    CONSENSO INFORMATO
    9. Essere in grado di fornire un consenso informato firmato.
    OPPURE
    10. Se i partecipanti non sono in grado di fornire il consenso informato scritto, saranno seguite procedure alternative di consenso come descritto nella Sezione 10.1.3 del protocollo.
    OPPURE
    11. Sarà richiesto che i partecipanti di età <18 anni firmino un modulo di assenso, oltre alla firma del consenso informato da parte di un genitore o tutore.
    E.4Principal exclusion criteria
    MEDICAL CONDITIONS
    1. Currently hospitalized or judged by the investigator as likely to
    require hospitalization in the next 24 hours
    2. Symptoms consistent with severe COVID-19 as defined by shortness
    of breath at rest or respiratory distress or requiring supplemental
    oxygen
    3. Participants who, in the judgement of the investigator are likely to die
    in the next 7 days.
    4. Known hypersensitivity to any constituent present in the
    investigational product
    PRIOR/CONCURRENT CLINICAL STUDY EXPERIENCE
    5. Enrollment in any investigational vaccine study within the last 180
    days or any other investigational drug study within 30 days prior to Day
    1 or within 5 half-lives of the investigational compound, whichever is
    longer
    6. Enrollment in any trial of an investigational drug, vaccine or device
    study for SARS-CoV-2/COVID-19 within 90 days prior to Day 1 or within
    5 half-lives of the investigational compound, whichever is longer
    OTHER EXCLUSIONS
    7. Receipt of convalescent plasma from a recovered COVID-19 patient or
    anti SARS-CoV-2 mAb within the last 3 months.
    8. Participants who, in the judgment of the investigator, will be unlikely
    or unable to comply with the requirements of the protocol through Day
    29

    NOTE: Previous receipt of a SARS-CoV-2/COVID-19 vaccine is NOT an
    exclusion criteria
    CONDIZIONI MEDICHE
    1. Attuale ricovero o probabile necessità di ricovero nelle successive 24 ore secondo il giudizio dello sperimentatore
    2. Sintomi coerenti con COVID-19 grave, definita da respiro corto a riposo o distress respiratorio o necessità di ossigeno supplementare
    3. Partecipanti che, a giudizio dello sperimentatore, rischiano il decesso nel corso dei successivi 7 giorni.
    4. Ipersensibilità nota a qualsiasi componente presente nel prodotto sperimentale

    ESPERIENZA PRECEDENTE/CONCOMITANTE IN STUDI CLINICI
    5. Arruolamento in qualsiasi studio su vaccini sperimentali negli ultimi 180 giorni o in qualsiasi altro studio su farmaci sperimentali nei 30 giorni precedenti il Giorno 1 o nelle 5 emivite del precedente composto sperimentale, a seconda del periodo più lungo
    6. Arruolamento in qualsiasi sperimentazione di un farmaco, vaccino o dispositivo sperimentale per SARS-CoV-2/COVID-19 nei 90 giorni precedenti il Giorno 1 o nelle 5 emivite del composto sperimentale, a seconda del periodo più lungo

    ALTRE ESCLUSIONI
    7. Ricezione di plasma convalescente da un paziente COVID-19 guarito o di mAb anti-SARS-CoV-2 negli ultimi 3 mesi.
    8. Partecipanti che, a giudizio dello sperimentatore, saranno non adatti o non in grado di rispettare i requisiti del protocollo fino al Giorno 29

    NOTA: la precedente ricezione di un vaccino contro SARS-CoV-2/COVID-19 NON è un criterio di esclusione
    E.5 End points
    E.5.1Primary end point(s)
    Progression of COVID-19 through Day 29 as defined by hospitalization >
    24 hours for acute management of illness due to any cause or death.
    Progressione della COVID-19 fino al Giorno 29 definita in base a ricovero >24 ore per la gestione acuta della malattia per qualsiasi causa o decesso.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Day 29
    Giorno 29
    E.5.2Secondary end point(s)
    •Occurrence of adverse events (AEs)
    •Occurrence of serious adverse events (SAEs)
    •Occurrence of adverse events of special interest (AESI)
    •Incidence and titers (if applicable) of serum anti-drug antibody (ADA)
    to VIR-7831 (sotrovimab)
    •Progression of COVID-19 through Day 29 as defined by visit to a
    hospital emergency room for management of illness OR hospitalization
    for acute management of illness for any duration and for any cause OR
    death
    •Development of severe and/or critical respiratory COVID-19 as
    manifested by
    requirement for respiratory support (including oxygen) at Day 8, Day 15,
    Day 22, and Day 29
    •Mean area under the curve of SARSCoV-2 viral load in nasal secretions
    as measured by qRT-PCR from Day 1 to Day 8 (AUCD1-8)
    •Change from baseline in viral load in nasal secretions by qRT-PCR at
    Day 8
    •Proportion of participants with a persistently high SARS-CoV-2 viral
    load at Day 8 by qRT-PCR
    •IV and IM sotrovimab pharmacokinetics (PK) in serum
    •Incidence of hospitalization through Day 29
    •Total hospital length of stay
    •Proportion of participants requiring ICU stay or mechanical ventilation
    through Day 29
    •Total ICU LOS
    •SARS-CoV-2 resistance mutants to sotrovimab at baseline
    •Emergence of viral resistance mutants to mAb by SARS-CoV-2
    •Change from baseline in viral load in nasal secretions by qRT-PCR
    during follow-up period at Day 5, Day 11, Day 15, Day 22 and Day 29
    • Undetectable SARS-CoV-2 in nasal secretions by qRT-PCR at Day 3, Day
    5, Day 8, Day 11, Day 15, Day 22 and Day 29
    • Mean area under the curve of SARSCoV-2 viral load as measured by
    qRT-PCR from Day 1 to Day 5 (AUCD1-5) and Day 1 to 11 (AUCD1-11)
    - Insorgenza di eventi avversi (AE)
    - Insorgenza di eventi avversi seri (SAE)
    - Insorgenza di eventi avversi di particolare interesse (AESI)
    - Incidenza e titoli (se pertinente) degli anticorpi anti-farmaco (ADA) contro VIR-7831 (sotrovimab) nel siero
    - Progressione della COVID-19 fino al Giorno 29 definita in base a visita in un pronto soccorso ospedaliero per la gestione della malattia OPPURE ricovero per la gestione acuta della malattia per qualsiasi durata e per qualsiasi causa OPPURE decesso
    - Sviluppo di COVID-19 respiratoria grave e/o critica come dimostrato da necessità di supporto respiratorio (incluso l'ossigeno) al Giorno 8, Giorno 15, Giorno 22 e Giorno 29
    - Area media sotto la curva della carica virale di SARS-CoV-2 nelle secrezioni nasali misurata secondo qRT-PCR dal Giorno 1 al Giorno 8 (AUCG1-8)
    - Variazione dal basale nella carica virale secondo qRT-PCR al Giorno 8
    - Percentuale di partecipanti con una carica virale di SARS-CoV-2 persistentemente elevata al Giorno 8 secondo qRT-PCR
    - Farmacocinetica (PK) di sotrovimab EV e IM nel siero
    - Incidenza del ricovero fino al Giorno 29
    - Degenza ospedaliera totale (LOS)
    - Percentuale di partecipanti che richiedono degenza in UTI o ventilazione meccanica fino al Giorno 29
    - LOS totale in UTI
    - Mutanti di SARS-CoV-2 con resistenza a sotrovimab al basale
    - Comparsa di mutanti virali di SARS-CoV-2 con resistenza al mAb
    - Variazione dal basale nella carica virale nelle secrezioni nasali secondo qRT-PCR durante il periodo di follow-up al Giorno 5, Giorno 11, Giorno 15, Giorno 22 e Giorno 29
    - SARS-CoV-2 non rilevabile nelle secrezioni nasali secondo qRT-PCR al Giorno 3, Giorno 5, Giorno 8, Giorno 11, Giorno 15, Giorno 22 e Giorno 29
    - Area media sotto la curva della carica virale di SARS-CoV-2 misurata secondo qRT-PCR dal Giorno 1 al Giorno 5 (AUCG1-5) e dal Giorno 1 al Giorno 11 (AUCG1-11)
    E.5.2.1Timepoint(s) of evaluation of this end point
    Day 1 to Day 5
    Day 1 to Day 8
    Day 1 to Day 11
    Day 3
    Day 5
    Day 8
    Day 11
    Day 15
    Day 22
    Day 29
    Note: Timepoints are specified for secondary end points in section E.5.2
    of this document.
    Dal Giorno 1 al giorno 5
    Dal Giorno 1 al giorno 8
    Dal Giorno 1 al giorno 11
    Giorno 3
    Giorno 5
    Giorno 8
    Giorno 11
    Giorno 15
    Giorno 22
    Giorno 29
    Nota: i momenti definiti sono specificati per gli endpoint secondari nella sezione E.5.2 di questo documento.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    VIR-7831 per via intramuscolare (IM) (2 dosaggi) rispetto a VIR-7831 per via endovenosa (EV)
    VIR-7831 (IM) (2 doses) against VIR-7831 (EV)
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned5
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA19
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Brazil
    Canada
    India
    Moldova, Republic of
    Peru
    South Africa
    Ukraine
    United States
    Austria
    France
    Italy
    Poland
    Romania
    Spain
    Argentina
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    A participant is considered to have completed the study if he/she has completed the Week 24 visit. The end of the study is defined as the date of the last contact of the last participant in the study.
    Si considera che un partecipante abbia completato lo studio se ha completato la visita della Settimana 24. La fine dello studio viene definita come la data dell'ultimo contatto dell'ultimo partecipante nello studio.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months10
    E.8.9.1In the Member State concerned days12
    E.8.9.2In all countries concerned by the trial years0
    E.8.9.2In all countries concerned by the trial months10
    E.8.9.2In all countries concerned by the trial days12
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 102
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 714
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 204
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Participants not capable of giving written informed consent
    Partecipanti non in grado di fornire il consenso informato scritto
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state48
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 200
    F.4.2.2In the whole clinical trial 1020
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Nessuno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-07-08
    N.Ethics Committee Opinion of the trial applicationWithdrawn
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-08-19
    P. End of Trial
    P.End of Trial Status
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 02:58:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA